

REMARKS

The Examiner has required restriction to one of the following inventions pursuant to 35 USC §121:

- Group I Claims 1-5, drawn to a method of identifying a nucleotide change in a TLR4 polynucleotide.
- Group II Claims 6-10, drawn to a method of identifying a therapeutic agent that reduces sensitivity to Gram-negative bacterial infection.
- Group III Claim 11, drawn to a therapeutic agent.
- Group IV Claim 12, drawn to a polynucleotide.
- Group V Claim 13, drawn to a polypeptide.

Applicant hereby elects to prosecute the claims of Group II (claims 6-10), drawn to a method of identifying a therapeutic agent that reduces sensitivity to Gram-negative bacterial infection, without traverse.

This constitutes a request for any needed extension of time and an authorization to charge all fees therefor to deposit account No. 19-5117, if not otherwise specifically requested. The undersigned hereby authorizes the charge of any fees created by the filing of this document or any deficiency of fees submitted herewith to deposit account No. 19-5117.

Respectfully submitted,


Mary Breen Smith, #43,512
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
(303) 268-0066

Dated: September 27, 2007

S:\Client\Folders\Evolutionary Genomics\200-3\2003.1\PCT\US\Response to Restriction Requirement.doc